The Global Conjugate Vaccines Market size is predicted to succeed in USD 10.14 billion by 2028. It's projected to grow at a CAGR of 25.9% over the forecast period. Increasing incidence of cancer and the growing geriatric population are likely to drive the marketplace for conjugate vaccines. Furthermore, major technological advancements also are contributing to drive expansion. Consistent with the World Health Organization (WHO), the number of individuals aged 65 years and above is projected to succeed 16% of the entire population by 2050 from 7% in 2000. Aging has become a considerable risk factor for varied diseases including cancer. Hence, the growing geriatric population is predicted to drive the growth of the market over the forecast period.
Until 2018, four conjugate vaccines were available within the market, namely Adcetris, Kadcyla, Besponsa, and Mylotarg. Owing to appropriate targeting and improved technology, conjugate vaccines are gaining tons of attention from both small and major pharmaceutical companies. Currently, there are approximately 50 conjugate vaccines in clinical trials and it's been projected that in the forecast period, three to four conjugate vaccines are going to be commercialized covering the areas of Refractory Hodgkin Lymphoma, Glioblastoma, Small Cell Carcinoma, Carcinoma, and Ovarian Cancer. It has been observed that the maximum number of clinical trials are being conducted for lymphoma. Seattle Genetics and Roche are leading the conjugate vaccines market in terms of market share. Until 2017 only two conjugate vaccines were commercially available – Adcetris by Seattle Genetics, and Kadcyla by Roche. Recently, two more Pfizer products were approved to be marketed for Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia. Hence, it's been estimated that over the forecast period, Pfizer is anticipated to realize a big market share.